Common Skin Rashes in Children: A Visual Guide for Parents

Topical corticosteroids are essential therapeutic tools for treating pediatric skin conditions including dermatitis, psoriasis, vitiligo, and burns, but their safe and effective use requires understanding proper indications, appropriate vehicle selection (creams, ointments, lotions, foams), correct potency selection (moderate potency preferred for children), appropriate dosing using the finger tip unit method, and limiting treatment duration to prevent adverse effects such as skin atrophy, striae, and tinea incognito; pediatricians should be comfortable managing these medications rather than always referring to specialists, as they can balance the benefits of effective treatment against the risks of adverse effects through careful monitoring and patient education.

Topical corticosteroids are essential for treating inflammatory pediatric skin conditions like atopic dermatitis, contact dermatitis, and psoriasis, with treatment duration typically 7-10 days for acute inflammation and intermittent use (2-3 days weekly) for maintenance; lower potency formulations should be used for children, with careful consideration of anatomical sites (higher absorption on eyelids, lower on palms/soles), and modern formulations like mometasone furoate offer excellent efficacy with minimal side effects, while addressing corticosteroid phobia through proper education about their safe and necessary use in pediatric dermatology.

Proper skin care is fundamental: daily baths shorter than 10 minutes with lukewarm water, gentle pat drying, hypoallergenic laundry detergents without fabric softeners, and appropriate moisturizers. Antihistamines are ineffective for pruritus (histamine accounts for <0.05% of causation) but may help with sleep if associated allergic conditions exist. Topical corticosteroids are the cornerstone of treatment and should not be feared—they are the most effective anti-pruritic and anti-inflammatory agents. Treatment should be initiated with low to medium potency corticosteroids, applied twice daily for at least 10 days. Proactive therapy with corticosteroids should continue for 2 months on previously affected areas to prevent rebound flares.

Advantan (methylprednisolone aceponate) is a topical corticosteroid with high lipophilicity, rapid penetration, and no halogen atoms (reduced side effects). It is indicated for atopic dermatitis, eczema, and allergic conditions. It can be used in children as young as 4 months. The therapeutic index favors Advantan over other corticosteroids. The correct sequence for applying topical corticosteroids and emollients is: (1) apply topical corticosteroid first to inflamed areas, (2) wait for absorption, (3) then apply emollient. This sequence maximizes the efficacy of the corticosteroid and prevents emollient-induced irritation.

Topical steroids are the mainstay of acute treatment, with hydrocortisone recommended for children and stronger steroids like betamethasone for adolescents and adults. Treatment duration should not exceed 20 days to prevent side effects. Oral antihistamines are essential adjunctive therapy, with sedating options for young children and non-sedating options for school-age children. Patients can develop tachyphylaxis (reduced response) to topical steroids with prolonged use, requiring alternative treatments like immunomodulators (tacrolimus, pimecrolimus) or biologic agents. Moisturization is the cornerstone of management, with products applied at least twice daily and as needed. Bathing should be limited to 10 minutes with neutral temperature water and fragrance-free, neutral soaps. Harsh products like scabicidal soaps or abrasive materials should be avoided.

This section covers three critical pediatric emergencies. Septic shock involves complex pathophysiology: increased vascular permeability from cytokines causes capillary leak; reduced venous return affects preload; vasoconstriction maintains organ perfusion; intravascular thrombosis occurs; myocardial dysfunction develops; electrolyte abnormalities cause arrhythmias. The pediatric traffic light system stratifies severity: Green (mild)—well-appearing with suspected infection; Yellow (moderate)—appears unwell to clinicians; Red (severe)—critical signs including non-blanching rash, bulging fontanelle, neck stiffness, or status epilepticus. Age under 3 months with temperature >38°C indicates rapid deterioration risk. Management protocol: blood cultures before antibiotics if febrile; lumbar puncture mandatory under 1 month; fluid bolus 20 ml/kg; third-generation cephalosporin for gram-negative coverage; amoxicillin added under 1 month for listeria; gentamicin for severely ill. Meningococcal septicemia presents with characteristic non-blanching purpuric rash from intravascular thrombosis—a unique distinguishing feature. Immediate treatment with IM benzyl penicillin in community settings, or IV ceftriaxone/cefotaxime in hospital. Anaphylaxis is a systemic allergic reaction involving cardiovascular and respiratory systems. Common triggers include foods (nuts most common), medications (penicillin and contrast agents particularly dangerous). Classic signs include throat/tongue swelling with sensation of closing, stridor, wheezing, exhaustion, tachycardia, hypertension, and erythema/rash. Mast cell tryptase testing confirms diagnosis 1-2 hours post-onset but should not delay treatment. Adrenaline is first-line: Under 6 kg = 0.05 mg; 6-12 kg = 0.1 mg; Above 12 kg = 0.3 mg (adult dose). Inject into anterolateral thigh, subsequent doses in opposite thigh.

The Spanish Society of Pediatrics (SEUP) developed a traffic light system to help parents determine when to seek medical care. Green (non-urgent): viral rashes that blanch, fever in children over 3 months without warning signs (wait 48-72 hours), cough/runny nose without respiratory difficulty, mild intermittent abdominal pain, red/itchy eyes, ear pain without fever. Amber (urgent): non-blanching spots, blanching rashes with swelling, fever in infants under 3 months, fever above 40.5°C, severe dizziness/weakness, respiratory difficulty, dehydration signs, foreign body ingestion, severe continuous abdominal pain. Red (immediate emergency): pale/grayish/bluish skin, anaphylaxis, unresponsiveness, suspected convulsions, severe respiratory distress, choking, deep wounds not stopping bleeding, open fractures, head injuries with loss of consciousness. Call 112 for red emergencies.

Pediatric emergency medicine requires rapid assessment because children can deteriorate very quickly. A personal example illustrates this: a 4-year-old child with a non-blanching rash became increasingly unwell, had a cardiac arrest, and died within approximately 30 minutes. Non-blanching rashes present a significant clinical challenge as 25-33% of children will have a non-blanching spot somewhere on their body. A systematic approach involves answering three questions: Is this child sick? Can I make a positive diagnosis? Can I safely discharge this child? Non-blanching rashes generally fall into three categories: mechanical causes (coughing/vomiting), vasculitic causes (HSP), and hematological causes (ITP, leukemia). Baseline investigations include FBC, CRP, blood culture, PCR, clotting screen, glucose, and blood gas. Children can be safely discharged if they remain well, have no purpura, the rash is not spreading, and baseline blood tests show normal CRP and white count. The PICK study is evaluating which protocols are most effective following the introduction of the meningococcal B vaccine in 2015. A significant concern is potential bias in assessing rashes in children with black or brown skin, as many educational resources predominantly feature white skin.

Pediatric emergency patients should be triaged into three groups: (1) Patients with life-threatening signs requiring immediate emergency intervention, (2) Patients with signs requiring priority assessment and treatment without delay, and (3) Patients without emergency signs who can be directed to appropriate outpatient or specialty care areas. According to Ministry of Health guidelines, there are six life-threatening signs requiring immediate intervention: (1) Airway obstruction, (2) Severe respiratory distress with central cyanosis, (3) Altered consciousness (lethargy, irritability, or coma), (4) Seizures, (5) Central cyanosis, and (6) Coma. These signs can be classified into three categories: respiratory system signs (airway obstruction, severe respiratory distress), circulatory system signs (central cyanosis, shock), and neurological system signs (altered consciousness, seizures). Early recognition of these signs is critical because conditions like cardiac arrest in children are often end-stage events with poor outcomes, while life-threatening signs can often be resolved with timely intervention.

Children with non-blanching rashes have approximately a 5% risk of serious infection, similar to general pediatric populations, but this risk varies significantly based on rash characteristics: purpura (purple discoloration) increases risk substantially compared to petechiae (small red spots), and well-appearing children with non-spreading rashes have very low risk; therefore, clinicians should treat any child with purpura and fever with antibiotics regardless of initial clinical suspicion, while well-appearing children with non-spreading rashes may not require routine invasive procedures.

Childhood exanthems are viral infections causing characteristic rashes in children. The classical list includes chickenpox (varicella), roseola (HHV-6/7), measles, rubella, and parvovirus B19 (fifth disease). Chickenpox presents with itchy crops of rash after a 1-3 day prodrome and can scar. Roseola causes high fevers with febrile seizures in children under five, followed by rash after fever subsides. Measles features the three C's (conjunctivitis, coryza, cough) with Koplik spots. Rubella has a pinkish rash and poses severe fetal risks in early pregnancy. Parvovirus B19 causes slapped cheek syndrome with risks to fetuses and patients with sickle cell disease. Vaccines now prevent chickenpox, measles, and rubella, reducing their prevalence.

Many serious rash-causing diseases are now preventable through vaccination, dramatically reducing childhood morbidity and mortality. Measles, rubella, meningococcal, and pneumococcal diseases—all potentially presenting with characteristic rashes—are effectively controlled through immunization programs. Recent declines in vaccination rates have led to resurgences of these diseases, including increased chickenpox and measles cases. Historical context shows these diseases caused widespread community illness and child deaths before vaccination. Contemporary pediatricians rarely encounter these severe conditions because vaccination has been so effective. Keeping children up-to-date with scheduled vaccines protects against potentially life-threatening illnesses.

This video explains how to differentiate between common childhood rashes including chickenpox (viral, vesicular rash progressing from papules to vesicles to crusts, low-grade fever, 7-10 day duration), measles (high fever up to 40°C, Koplik spots, cough, runny nose), German measles/rubella (lower fever, lymphadenopathy, potentially affecting testicles), and scarlet fever (bacterial streptococcal infection with characteristic strawberry tongue and blanching rash). The video also outlines the governmental vaccination schedule: BCG at birth, DPT at 2, 4, 6 months, hepatitis B at 2, 4, 6 months, MMR at 1 year with booster, rotavirus from 1.5 months, pneumococcal from 2 months, meningococcal from 2 months, chickenpox at 1-1.5 years, and meningococcal booster every 2 years until age 18.

This comprehensive overview covers the childhood vaccination schedule and the diseases they prevent. At 2 and 4 months, children receive the rotavirus vaccine (two oral doses of 15ml each) and the inactivated polio vaccine (two intradermal doses of 0.1ml each). The rotavirus vaccine prevents acute diarrhea characterized by vomiting, liquid diarrhea lasting 3-8 days, fever, abdominal pain, and dehydration. Children can be reinfected since neither vaccine nor natural infection provides complete immunity. The polio vaccine prevents polio, a potentially fatal disease causing paralysis. Polio spreads through person-to-person contact via respiratory droplets and contaminated food/water, with infected individuals transmitting the virus before and after symptoms appear.

Maculopapular rashes are flat, slightly raised red eruptions important for diagnosis. Measles presents with sore throat, cough, conjunctivitis, and characteristic rash. Before vaccination, it killed 6 million annually; since 2002, deaths dropped 74% due to MMR vaccine (live attenuated, 20-year protection). Complications include otitis media, pneumonia, and SSPE (1 in 1,000 cases), a progressive neurological degeneration destroying neurons and myelin. Transmission is by respiratory droplets, making it highly contagious. Rubella (German measles) presents with pink macules and papules starting on the face, resolving in 3 days. The major concern is congenital rubella syndrome when contracted by pregnant women, causing deafness, heart abnormalities, and mental retardation. Rubella virus (Togaviridae) is teratogenic, stopping cellular mitosis and causing apoptosis. Fifth disease (parvovirus B19) presents with slapped cheek appearance and mild illness, highly contagious in daycare settings. Roseola (HHV-6) causes high fever and rash, remaining latent indefinitely. All require palliative care except measles and rubella, which are preventable through vaccination.